Idarubicinhydrochlorid Accord

Idarubicin, the active ingredient in Idarubicinhydrochlorid Accord, is an anthracycline antibiotic presented as an injection solution for intravenous use. It treats acute myeloid leukemia in adult patients, targeting rapidly dividing malignant cells. GNH USA supplies Idarubicinhydrochlorid Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide, ensuring quality and regulatory compliance.

Idarubicin is an anthracycline used in the treatment of hematologic malignancies, primarily acute myeloid leukemia.

Acute Myeloid Leukemia (newly diagnosed): induces remission and improves overall survival. Relapsed or refractory AML: provides an additional therapeutic option after prior regimens. High‑risk AML subtypes: contributes to disease control when combined with other agents.

Idarubicin may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea and vomiting - Myelosuppression (neutropenia, anemia, thrombocytopenia) - Alopecia (hair loss) - Mucositis (mouth and gastrointestinal inflammation)

Serious or Rare Side Effects: - Cardiotoxicity (reduced left‑ventricular function, congestive heart failure) - Severe infections due to neutropenia - Acute infusion‑related reactions (hypotension, dyspnea) - Secondary malignancies (therapy‑related leukemia).

When using Idarubicinhydrochlorid Accord, clinicians should observe several safety measures.

Cardiac monitoring: assess baseline and periodic ejection fraction. Hematologic surveillance: perform regular complete blood counts. Infection risk: implement prophylactic antimicrobials as indicated. Pregnancy and lactation: avoid use unless benefits outweigh potential fetal or infant risks. Drug compatibility: verify IV line compatibility before administration. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Idarubicin can interact with other medicines, altering efficacy or toxicity.

Major Interactions (Avoid): - Concurrent anthracyclines or cardiotoxic agents: increase risk of cardiac damage. - Strong CYP3A4 inhibitors (e.g., ketoconazole): raise plasma concentrations. - Live vaccines: risk of uncontrolled infection due to immunosuppression.

Moderate Interactions (Monitor Closely): - Anticoagulants (warfarin): may enhance bleeding risk. - Myelosuppressive agents (e.g., cytarabine): additive bone‑marrow suppression. - Electrolyte‑altering drugs (e.g., diuretics): monitor for arrhythmias.